The importance of early stage clinical trials in oncology is increasing. Historically, cancer patients participated in phase 1 trials because this was the only option for those with advanced cancer that would not respond to standard treatment. Today, more patients are interested in participating not because it is a last resort for them, but because they gain access to new treatment alternatives to chemotherapy, and there are larger trials which benefit more patients. (SCIENMAG)